about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuTumour immunology, vaccination and escape strategiesThe role of the Major Histocompatibility Complex in the spread of contagious cancersExclusion of lipid rafts and decreased mobility of CD94/NKG2A receptors at the inhibitory NK cell synapse.Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.Distinct functions of the ATP binding cassettes of transporters associated with antigen processing: a mutational analysis of Walker A and B sequences.Inference of high resolution HLA types using genome-wide RNA or DNA sequencing readsThe relationship between human leukocyte antigens (HLA) and renal cell carcinomaActivation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.On guard--activating NK cell receptors.An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexesImmune profiling and cancer post transplantationImmunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus.Gene therapy of liver diseases.Challenges and future perspectives of T cell immunotherapy in cancerExploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.T-cell modulatory properties of CD5 and its role in antitumor immune responsesDendritic cell density and activation status in human breast cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression.Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directionsNK cells and cancer immunosurveillance.HLA Class I Allele Frequencies in Southern Iranian Women with Breast CancerOn the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.Immune escape mechanisms of intraocular tumors.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells.Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma.Activation of cytokine-producing and antitumor activities of natural killer cells and macrophages by engagement of Toll-like and NOD-like receptors.Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.Targetless T cells in cancer immunotherapy.Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols.Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules.Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants.Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production.
P2860
Q21131200-6CBE7D31-EE56-4FC5-B190-D9F317887128Q28208633-FCA74C19-4ED6-4F39-A607-1D0F173C66DAQ28296253-8A1BF4F4-72A9-4AC7-B8A1-A8AAFAA32E64Q30660019-3AB5C61A-D4E2-479E-B02B-C1B2930C1F78Q31148056-2BEF9E83-D84C-4062-BE70-6CC57F6E400DQ33181866-00C2F35E-8F0A-4F73-B297-3BA4877B2E04Q33669140-086488FA-3009-41A4-8536-325E7AC3500DQ33847917-3DADE1C3-9EA2-4390-82D7-DBE72831DFB5Q34059205-D7BA70DD-DE3A-450F-95D7-71A74A9D4D68Q34117069-C2FDA409-0CD2-4A29-81D0-32C2F8AFF202Q34359447-936BA4F1-DE90-4041-BB62-AC20DCB9C30FQ35050810-51BB4702-B96E-443C-BEF1-92D0F84F4A3EQ35142329-16A4B19B-952B-4A24-A20B-5865474F6F39Q35770325-3A4C8538-0999-4841-9CC4-078D386746A2Q35842662-D43E14CD-D007-4956-BF34-386953F161D6Q35843507-BC5430E2-E882-40CB-ADE1-D50C8E615B57Q35887319-E0F0B319-2085-4006-83ED-6A6643759848Q35959307-FD2AF913-1F60-4512-B75A-C3BDA07D409DQ36643675-1BA5CBBF-73C4-4760-8441-30C319A3CAE9Q36644140-73C1AE1D-E1AD-4473-B817-91CDA7010266Q36954166-0AA07BD1-975E-453D-9786-D96B0CFCEB95Q37287176-D7FB2A03-D50F-4EC5-A881-626EFD7B2B97Q37350666-79B99CFB-DF39-4545-B51B-B3E818D00EF0Q37354975-CFE8C3D3-91F3-466B-940E-7B0FD0AADE7BQ37535138-C66233A7-7E31-4859-A613-81A6A28B5E2CQ37970682-18E01DCC-479D-46D8-B4A0-937C4A188BFEQ38652319-0C50846D-C4C5-45AC-9DF9-71923A69E75BQ38802286-270DED2B-22C8-4916-887F-A2C6E71178E3Q39672046-84BA0B5B-A8DC-4DBC-B0D5-C6F1899E3F02Q39767227-5EF227F7-19AB-4335-9834-B17570DBC877Q40322821-2FC1319D-848F-4A0C-97C5-49BE6DD13317Q40744650-C9FD7FC3-F7CA-4C13-A094-F6721CEADA93Q40827292-8A7D3B19-7076-4EBD-8856-663F21F44660Q41150808-846C32A5-F813-4A4F-9F59-4DD40EB420EFQ41654263-40C7F6D4-85C9-465E-A361-EB82A2EBCA72Q42498205-E9DC3874-78DB-42DD-9B95-54D0C1B5F55EQ42792479-90F4E8E8-84AB-490B-965F-E6E2B07820D1Q43773475-C0B2B8A0-0560-4D5D-AC8D-884F5D95E179Q43861066-29ACACC1-63E5-4276-878F-513B235D267CQ44253376-91E3BC88-282E-4DBE-BCF6-56DCAE0DDA1E
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The HLA crossroad in tumor immunology.
@ast
The HLA crossroad in tumor immunology.
@en
type
label
The HLA crossroad in tumor immunology.
@ast
The HLA crossroad in tumor immunology.
@en
prefLabel
The HLA crossroad in tumor immunology.
@ast
The HLA crossroad in tumor immunology.
@en
P2093
P1433
P1476
The HLA crossroad in tumor immunology.
@en
P2093
P356
10.1016/S0198-8859(99)00156-1
P577
2000-01-01T00:00:00Z